Venetoclax, a BCL-2 Inhibitor, Enhances the Efficacy of Chemotherapeutic Agents in Wild-Type ABCG2-Overexpression-Mediated MDR Cancer Cells
Open Access
Abstract
Previous studies have shown that small-molecule BCL-2 inhibitors can have a synergistic interaction with ABCG2 substrates in chemotherapy. Venetoclax is a potent and selective BCL-2 inhibitor, approved by the FDA in 2016 for the treatment of patients with chronic lymphocytic leukemia (CLL). This study showed that, at a non-toxic concentration, venetoclax at 10 µM significantly reversed multidrug resistance (MDR) mediated by wild-type ABCG2, without significantly affecting MDR mediated by mutated ABCG2 (R482G and R482T) and ABCB1, while moderate or no reversal effects were observed at lower concentrations (0.5 to 1 µM). The results showed that venetoclax increased the intracellular accumulation of chemotherapeutic agents, which was the result of directly blocking the wild-type ABCG2 efflux function and inhibiting the ATPase activity of ABCG2. Our study demonstrated that venetoclax potentiates the efficacy of wild-type ABCG2 substrate drugs. These findings may provide useful guidance in combination therapy against wild-type ABCG2-mediated MDR cancer in clinical practice.Keywords
Funding Information
- Department of Pharmaceutical Sciences, St. John’s University (N/A)
This publication has 62 references indexed in Scilit:
- Dicer-Mediated Upregulation of BCRP Confers Tamoxifen Resistance in Human Breast Cancer CellsClinical Cancer Research, 2011
- Sildenafil Reverses ABCB1- and ABCG2-Mediated Chemotherapeutic Drug ResistanceCancer Research, 2011
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer TherapyClinical Cancer Research, 2009
- Involvement of Multiple Transporters in the Hepatobiliary Transport of RosuvastatinDrug Metabolism and Disposition, 2008
- The nature of amino acid 482 of human ABCG2 affects substrate transport and ATP hydrolysis but not substrate bindingProtein Science, 2006
- Gefitinib (“Iressa”, ZD1839), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses Breast Cancer Resistance Protein/ABCG2–Mediated Drug ResistanceCancer Research, 2005
- Arginine482 to threonine mutation in the breast cancer resistance protein ABCG2 inhibits rhodamine 123 transport while increasing bindingBiochemical Journal, 2004
- Transport of 7-Ethyl-10-hydroxycamptothecin (SN-38) by Breast Cancer Resistance Protein ABCG2 in Human Lung Cancer CellsBiochemical and Biophysical Research Communications, 2001
- Induction of Apoptosis by Cancer ChemotherapyExperimental Cell Research, 2000